Skip to main content

Table 1 Sample characteristic according to the presence of clinical lipodystrophy

From: Impact of Lipodystrophy on the prevalence and components of metabolic syndrome in HIV-infected patients

  Without CL With CL P
n (%) 139 (39.6) 206 (58.7)  
Sex [n(%)]    
   Male 85 (61.2) 154 (74.8) 0.007
   Female 54 (38.8) 52 (25.2)  
Age [years, median (25th and 75th percentiles)] 42.0 (34.0-51.0) 45.0 (39.0-54.0) 0.006
Duration of HIV infection [years, median (25th and 75th percentiles)] 6.0 (4.0-9.0) 9.0 (6.0-11.0) < 0.001
cART [years, median (25th and 75th percentiles)] 4.0 (2.0-7.0) 8.0 (5.0-10.0) < 0.001
Weight [Kg, mean (sd)] 73.6 (14.1) 66.2 (12.4) < 0.001
Height [m, mean (sd)] 1.65 (0.09) 1.66 (0.09) 0.430
BMI [(kg/m2), mean (sd)] 27.0 (5.0) 24.0 (3.9) < 0.001
Waist circumference [cm, mean (sd)] 95.4 (13.0) 89.5 (10.5) < 0.001
Systolic BP [mmHg, median (25th and 75th percentiles)] 120.0 (110.0-135.0) 120.0 (110.0-135.0) 0.871
Diastolic BP [mmHg, median (25th and 75th percentiles)] 80.0 (70.0-80.0) 80.0 (70.0-80.0) 0.765
CD4 cell count [cells/mm3, median (25th and 75th percentiles)] 446.5 (291.5-633.8) 544.0 (362.0-749.0) 0.008
HIV RNA (< 50) [n (%)] 94 (82.5) 163 (91.1) 0.029
Hepatitis C co-infection [n (%)] 31 (25) 58 (31.4) 0.227
HIV risk factor [n (%)]    
   Intravenous drug user 28 (24.6) 52 (30.6)  
   Homosexual contact 10 (8.8) 19 (11.2)  
   Heterosexual contact 75 (65.8) 90 (52.9)  
   Others 1 (0.9) 9 (5.3) 0.073
CDC [n (%)]    
   A 62 (54.9) 94 (53.4)  
   B 4 (3.5) 0 (0.0)  
   C 47 (41.6) 82 (46.6) 0.037
ART [n (%)]    
IP 67 (61.5) 98 (55.4) 0.310
NNRTI 47 (43.1) 83 (46.9) 0.534
NRTI 104 (95.4) 175 (98.9) 0.066
Smoking history [n (%)]    
   Never 60 (43.5) 70 (34.8)  
   Current 56 (40.6) 93 (46.3)  
   Former 22 (15.9) 38 (18.9) 0.272
Glucose [mg/dL, median (25th and 75th percentiles)] 91.0 (84.0-108.0) 94.5 (863.0-117.0) 0.074
Total cholesterol [mg/dL, mean (sd)] 229.5 (59.8) 220.7 (59.5) 0.182
HDL- cholesterol [mg/dL, median (25th and 75th percentiles)] 48.0 (37.0-55.0) 43.0 (35.0-53.0) 0.047
Triglycerides [mg/dL, median (25th and 75th percentiles)] 192.0 (126.0-323.0) 231.0 (149.8-365.8) 0.016
Metabolic syndrome ATP III [n (%)] 71 (51.1) 109 (52.9) 0.738
Metabolic syndrome IDF [n (%)] 64 (46.0) 85 (41.3) 0.379
Metabolic syndrome features - ATP III    
   High blood pressure 61 (43.9) 87 (42.4) 0.790
   Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
   Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
   High waist circumference 58 (41.7) 46 (22.3) < 0.001
   High fasting glucose 51 (36.7) 84 (40.8) 0.446
Number of metabolic syndrome features ATP III    
0 6 (4.3) 9 (4.4) 0.242
1 25 (18.0) 19 (9.3)  
2 37 (26.6) 69 (33.7)  
3 31 (22.3) 52 (25.4)  
4 31 (22.3) 42 (20.5)  
5 9 (6.5) 14 (6.8)  
Metabolic syndrome features - IDF    
   High blood pressure 61 (43.9) 87 (42.4) 0.790
   Hypertriglyceridemia 98 (70.5) 177 (85.9) < 0.001
   Low HDL cholesterol 93 (66.9) 160 (77.7) 0.027
   High waist circumference 87 (62.6) 94 (45.6) 0.002
   High fasting glucose 51 (36.7) 80 (38.8) 0.687
Number of metabolic syndrome features IDF    
0 5 (3.6) 9 (4.4) 0.263
1 19 (13.7) 17 (8.3)  
2 35 (25.2) 51 (24.9)  
3 32 (23.0) 63 (30.7)  
4 35 (25.2) 39 (19.0)  
5 13 (9.4) 26 (12.7)  
  1. Note - CL = Clinical lipodystrophy, MS = Metabolic syndrome; ATPIII = Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; IDF = International Diabetes Federation; BMI = body mass index.